| univariate analysis | ||||
---|---|---|---|---|---|
 | score | n | 5 year survival rate | SE | p value |
pT | 2 | 24 | 100 | Â | 0.226 |
 | 3 | 255 | 85.6 | 2.2 |  |
 | 4 | 31 | 83.0 | 6.9 |  |
grading | low-grade | 257 | 86.9 | 2.2 | 0.446 |
 | high-grade | 53 | 84.8 | 5 |  |
lymph node status | N0 or II | 178 | 92.1 | 2.1 | <0.001 |
or stage | N+ or III | 132 | 79.5 | 3.5 | Â |
vessel infiltration | V0 | 285 | 89.0 | 1.9 | <0.001 |
 | V1 | 24 | 58.3 | 10.1 |  |
chemotherapy | applied | 261 | 87.1 | 2.1 | 0.700 |
 | not applied | 49 | 83.5 | 5.3 |  |
TGF-β1 in tumour | low (0–1) | 209 | 85.5 | 2.5 | 0.462 |
 | high (2–3) | 99 | 88.6 | 3.2 |  |
Smad3 in tumour | negative | 133 | 88.1 | 2.9 | 0.941 |
 | positive | 176 | 85.3 | 2.7 |  |
Smad4 in tumour | negative | 44 | 92.5 | 4.2 | 0.896 |
 | positive | 261 | 85.4 | 2.2 |  |
TGF-β-R1 in stroma | negative | 122 | 83.8 | 3.4 | 0.121 |
 | positive | 188 | 88.3 | 2.4 |  |
TGF-β R2 in stroma | negative | 123 | 82.3 | 3.5 | 0.003 |
 | positive | 186 | 89.3 | 2.3 |  |
 | multivariate analysis | ||||
 | score | n | relative risk RR | 95% confidence intervall | p value |
TGF-β R2 in stroma | negative | 122 | 1 |  |  |
 | positive | 186 | 2.2 | 1.2–3.8 | 0.007 |
lymph node status | N0 | 177 | 1 | Â | Â |
 | N+ | 131 | 2.1 | 1.2–3.8 | 0.012 |
vessel infiltration | V0 | 284 | 1 | Â | Â |
 | V1 | 24 | 4.1 | 2.1–7.9 | <0.001 |